Cancer immunotherapy: On the trail of a cure?

Thomas S. Griffith, Troy J. Kemp, Aaron T. Ludwig, Jill M. Moore, Rebecca L. Vanoosten

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Since its discovery in 1995, numerous studies have investigated the potential of using TRAIL (TNF-related apoptosis-inducing ligand) as an alternative cancer therapeutic, since it is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. As a consequence, a great deal is known about TRAIL/TRAIL receptor expression, the molecular mechanism of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Translating the preclinical TRAIL studies into the clinic is beginning, with the hope that TRAIL will retain all of its tumoricidal activity against human primary tumors in situ with no toxic side effects.

Original languageEnglish (US)
Title of host publicationApplication of Apoptosis to Cancer Treatment
PublisherSpringer Netherlands
Pages247-270
Number of pages24
ISBN (Print)1402033036, 9781402033032
DOIs
StatePublished - Dec 1 2005

Keywords

  • TRAIL
  • adenovirus
  • apoptosis
  • immunotherapy
  • tumor

Fingerprint Dive into the research topics of 'Cancer immunotherapy: On the trail of a cure?'. Together they form a unique fingerprint.

  • Cite this

    Griffith, T. S., Kemp, T. J., Ludwig, A. T., Moore, J. M., & Vanoosten, R. L. (2005). Cancer immunotherapy: On the trail of a cure? In Application of Apoptosis to Cancer Treatment (pp. 247-270). Springer Netherlands. https://doi.org/10.1007/1-4020-3302-8_11